Phibro Animal Health Competitors

Emergent BioSolutions (NYSE:EBS) and Phibro Animal Health (NASDAQ:PAHC) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.

Volatility and Risk

Emergent BioSolutions has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.

Earnings & Valuation

This table compares Emergent BioSolutions and Phibro Animal Health's revenue, earnings per share and valuation.

Emergent BioSolutions has higher revenue and earnings than Phibro Animal Health. Phibro Animal Health is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Emergent BioSolutions and Phibro Animal Health, as provided by MarketBeat.com.

Emergent BioSolutions currently has a consensus price target of $113.6667, suggesting a potential upside of 52.94%. Phibro Animal Health has a consensus price target of $21.50, suggesting a potential downside of 11.85%. Given Emergent BioSolutions' stronger consensus rating and higher probable upside, equities analysts clearly believe Emergent BioSolutions is more favorable than Phibro Animal Health.

Profitability

This table compares Emergent BioSolutions and Phibro Animal Health's net margins, return on equity and return on assets.

Insider and Institutional Ownership

80.2% of Emergent BioSolutions shares are held by institutional investors. Comparatively, 50.3% of Phibro Animal Health shares are held by institutional investors. 14.1% of Emergent BioSolutions shares are held by insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Emergent BioSolutions beats Phibro Animal Health on 13 of the 14 factors compared between the two stocks.

Turning Point Therapeutics (NASDAQ:TPTX) and Phibro Animal Health (NASDAQ:PAHC) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.

Volatility and Risk

Turning Point Therapeutics has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.

Earnings & Valuation

This table compares Turning Point Therapeutics and Phibro Animal Health's revenue, earnings per share and valuation.

Phibro Animal Health has higher revenue and earnings than Turning Point Therapeutics. Turning Point Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Turning Point Therapeutics and Phibro Animal Health, as provided by MarketBeat.com.

Turning Point Therapeutics currently has a consensus price target of $153.7143, suggesting a potential upside of 102.82%. Phibro Animal Health has a consensus price target of $21.50, suggesting a potential downside of 11.85%. Given Turning Point Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Turning Point Therapeutics is more favorable than Phibro Animal Health.

Profitability

This table compares Turning Point Therapeutics and Phibro Animal Health's net margins, return on equity and return on assets.

Insider and Institutional Ownership

81.3% of Turning Point Therapeutics shares are held by institutional investors. Comparatively, 50.3% of Phibro Animal Health shares are held by institutional investors. 23.2% of Turning Point Therapeutics shares are held by insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Phibro Animal Health beats Turning Point Therapeutics on 8 of the 13 factors compared between the two stocks.

Agios Pharmaceuticals (NASDAQ:AGIO) and Phibro Animal Health (NASDAQ:PAHC) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.

Volatility and Risk

Agios Pharmaceuticals has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.

Insider and Institutional Ownership

92.9% of Agios Pharmaceuticals shares are held by institutional investors. Comparatively, 50.3% of Phibro Animal Health shares are held by institutional investors. 3.2% of Agios Pharmaceuticals shares are held by insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Agios Pharmaceuticals and Phibro Animal Health's revenue, earnings per share and valuation.

Phibro Animal Health has higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Agios Pharmaceuticals and Phibro Animal Health's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current recommendations and price targets for Agios Pharmaceuticals and Phibro Animal Health, as provided by MarketBeat.com.

Agios Pharmaceuticals currently has a consensus price target of $64.6364, suggesting a potential upside of 19.50%. Phibro Animal Health has a consensus price target of $21.50, suggesting a potential downside of 11.85%. Given Agios Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Agios Pharmaceuticals is more favorable than Phibro Animal Health.

Summary

Phibro Animal Health beats Agios Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

I-Mab (NASDAQ:IMAB) and Phibro Animal Health (NASDAQ:PAHC) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Insider & Institutional Ownership

16.6% of I-Mab shares are held by institutional investors. Comparatively, 50.3% of Phibro Animal Health shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares I-Mab and Phibro Animal Health's revenue, earnings per share (EPS) and valuation.

Phibro Animal Health has higher revenue and earnings than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares I-Mab and Phibro Animal Health's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and target prices for I-Mab and Phibro Animal Health, as provided by MarketBeat.

I-Mab currently has a consensus price target of $70.00, suggesting a potential upside of 26.13%. Phibro Animal Health has a consensus price target of $21.50, suggesting a potential downside of 11.85%. Given I-Mab's stronger consensus rating and higher probable upside, research analysts plainly believe I-Mab is more favorable than Phibro Animal Health.

Summary

Phibro Animal Health beats I-Mab on 9 of the 13 factors compared between the two stocks.

Legend Biotech (NASDAQ:LEGN) and Phibro Animal Health (NASDAQ:PAHC) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Insider & Institutional Ownership

18.9% of Legend Biotech shares are held by institutional investors. Comparatively, 50.3% of Phibro Animal Health shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Legend Biotech and Phibro Animal Health's revenue, earnings per share (EPS) and valuation.

Phibro Animal Health has higher revenue and earnings than Legend Biotech.

Profitability

This table compares Legend Biotech and Phibro Animal Health's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and target prices for Legend Biotech and Phibro Animal Health, as provided by MarketBeat.

Legend Biotech currently has a consensus price target of $50.6667, suggesting a potential upside of 87.93%. Phibro Animal Health has a consensus price target of $21.50, suggesting a potential downside of 11.85%. Given Legend Biotech's stronger consensus rating and higher probable upside, research analysts plainly believe Legend Biotech is more favorable than Phibro Animal Health.

Summary

Phibro Animal Health beats Legend Biotech on 7 of the 11 factors compared between the two stocks.

Nektar Therapeutics (NASDAQ:NKTR) and Phibro Animal Health (NASDAQ:PAHC) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Volatility and Risk

Nektar Therapeutics has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.

Insider & Institutional Ownership

95.3% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 50.3% of Phibro Animal Health shares are held by institutional investors. 3.0% of Nektar Therapeutics shares are held by insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Nektar Therapeutics and Phibro Animal Health's revenue, earnings per share (EPS) and valuation.

Phibro Animal Health has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nektar Therapeutics and Phibro Animal Health's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and target prices for Nektar Therapeutics and Phibro Animal Health, as provided by MarketBeat.

Nektar Therapeutics currently has a consensus price target of $25.2857, suggesting a potential upside of 30.34%. Phibro Animal Health has a consensus price target of $21.50, suggesting a potential downside of 11.85%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Nektar Therapeutics is more favorable than Phibro Animal Health.

Summary

Phibro Animal Health beats Nektar Therapeutics on 8 of the 14 factors compared between the two stocks.